The New England Journal of Medicine today shared landmark results from the EMPA-REG OUTCOME trial. The study revealed a marked reduction in cardiovascular (CV) mortality and morbidity for high CV risk type 2 diabetes patients when taking empagliflozin (a sodium glucose cotransporter 2 inhibitor).
Throughout the randomized, double-blind, placebo-controlled trial, all cardiovascular events were prospectively adjudicated by an independent committee of medical experts, managed by ACI Clinical. This met FDA Guidance recommendations to demonstrate that a new type 2 diabetes therapy does not increase CV risk.
As provider of the study’s CV Endpoint Adjudication Committee services, ACI Clinical is honored to have supported the EMPA-REG OUTCOME trial. By demonstrating a reduction in CV mortality and morbidity, this important study is a milestone in CV outcomes for anti-diabetic therapies.
New England Journal of Medicine article
Additional news stories
- CBS News: Type 2 Diabetes Pill Cuts Risk of Death
- Wall Street Journal: New Diabetes Drug Shows Sharply Reduced Risk of Heart Related Death
- Medscape: Diabetes Drug Empagliflozin Cuts CV Deaths in Landmark EMPA-REG Trial
- CardioBrief: Has the Holy Grail of Diabetes Management Finally Been Reached?